Biology subjects

Gcwensa, N. Z.

Publications and source records attributed to Gcwensa, N. Z..

3 recordsLinked to original sources

bioRxiv2025

Aggregated α-synuclein leads to corticostriatal synaptic dysfunction

Neuronal inclusions of -synuclein (-syn) are pathological hallmarks of Parkinsons disease (PD) and Dementia with Lewy Bodies (DLB). -Syn pathology accumulates in cortical neurons which project to the striatum. To begin to understand how -syn pathology effects cortico-striatal synapses, pre-formed -syn fibrils (PFF) were injected into the striatum to induce robust -syn aggregation in corticostriatal-projecting neurons. Electrophysiological recordings of striatal spiny projection neurons (SPNs) acute slices found a significant decrease in evoked corticostriatal glutamate release in mice with PFF-induced aggregates compared to monomer injected mice. Expansion microscopy, confocal microscopy and Imaris reconstructions were used to identify vGLUT1 positive presynaptic terminals juxtaposed to Homer-positive postsynaptic densities, termed synaptic foci. Quantitation of synaptic loci density revealed a loss of corticostriatal synapses. Immunoblots of the striatum show reductions in expression of pre-synaptic proteins with selective reduction in AMPA and NMDA receptor subunits in mice with -syn aggregates compared to controls. Paradoxically, a small percentage of remaining VLGUT1+ synaptic loci with small, intrasynaptic -syn aggregates showed enlarged volumes compared to nearby synapses without -syn aggregates. Our combined physiology and high-resolution imaging data point to dysfunction of corticostriatal synapses in mice harboring {square}-synuclein inclusions, which may contribute to impaired basal ganglia circuitry in PD. Highlights- Corticostriatal glutamate drive is impaired in the presence of pathological -syn - -Syn aggregation causes early loss of corticostriatal synapses - Synaptic loci positive for small -syn aggregates show volume increases - Striatal expression of select synaptic proteins are reduced in animals with -syn pathology

neuroscience↗

bioRxiv2024

Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein

Parkinsons disease (PD) and Dementia with Lewy bodies (DLB) are characterized by neuronal -synuclein (-syn) inclusions termed Lewy Pathology, which are abundant in the amygdala. The basolateral amygdala (BLA), in particular, receives projections from the thalamus and cortex. These projections play a role in cognition and emotional processing, behaviors which are impaired in -synucleinopathies. To understand if and how pathologic -syn impacts the BLA requires animal models of -syn aggregation. Injection of -synuclein pre-formed fibrils (PFFs) into the striatum induces robust -synuclein aggregation in excitatory neurons in the BLA that corresponds with reduced contextual fear conditioning. At early time points after aggregate formation, cortico-amygdala excitatory transmission is abolished. The goal of this project was to determine if -syn inclusions in the BLA induce synaptic degeneration and/or morphological changes. In this study, we used C57BL/6J mice injected bilaterally with PFFs in the dorsal striatum to induce -syn aggregate formation in the BLA. A method was developed using immunofluorescence and three-dimensional reconstruction to analyze excitatory cortico-amygdala and thalamo-amygdala presynaptic terminals closely juxtaposed to postsynaptic densities. The abundance and morphology of synapses were analyzed at 6- or 12-weeks post-injection of PFFs. -Syn aggregate formation in the BLA did not cause a significant loss of synapses, but cortico-amygdala and thalamo-amygdala presynaptic terminals and postsynaptic densities with aggregates of -synuclein show increased volumes, similar to previous findings in human DLB cortex, and in non-human primate models of PD. Transmission electron microscopy showed that PFF-injected mice showed reduced intervesicular distances similar to a recent study showing phospho-serine-129 -synuclein increases synaptic vesicle clustering. Thus, pathologic -synuclein causes major alterations to synaptic architecture in the BLA, potentially contributing to behavioral impairment and amygdala dysfunction observed in synucleinopathies.

neuroscience↗

bioRxiv2021

Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein

Pathologic inclusions composed of -synuclein called Lewy pathology are hallmarks of Parkinsons Disease (PD). Dominant inherited mutations in leucine rich repeat kinase 2 (LRRK2) are the most common genetic cause of PD. Lewy pathology is found in the majority of individuals with LRRK2-PD, particularly those with the G2019S-LRRK2 mutation. Lewy pathology in LRRK2-PD associates with increased non-motor symptoms such as cognitive deficits, anxiety, and orthostatic hypotension. Thus, understanding the relationship between LRRK2 and -synuclein could be important for determining the mechanisms of non-motor symptoms. In PD models, expression of mutant LRRK2 reduces membrane localization of - synuclein, and enhances formation of pathologic -synuclein, particularly when synaptic activity is increased. -Synuclein and LRRK2 both localize to the presynaptic terminal. LRRK2 plays a role in membrane traffic, including axonal transport, and therefore may influence -synuclein synaptic localization. This study shows that LRRK2 kinase activity influences -synuclein targeting to the presynaptic terminal. We used the selective LRRK2 kinase inhibitors, MLi-2 and PF-06685360 (PF-360) to determine the impact of reduced LRRK2 kinase activity on presynaptic localization of -synuclein. Expansion microscopy (ExM) in primary hippocampal cultures and the mouse striatum, in vivo, was used to more precisely resolve the presynaptic localization of -synuclein. Live imaging of axonal transport of -synuclein-GFP was used to investigate the impact of LRRK2 kinase inhibition on -synuclein axonal transport towards the presynaptic terminal. Reduced LRRK2 kinase activity increases -synuclein overlap with presynaptic markers in primary neurons, and increases anterograde axonal transport of - synuclein-GFP. In vivo, LRRK2 inhibition increases -synuclein overlap with glutamatergic, cortico-striatal terminals, and dopaminergic nigral-striatal presynaptic terminals. The findings suggest that LRRK2 kinase activity plays a role in axonal transport, and presynaptic targeting of -synuclein. These data provide potential mechanisms by which LRRK2-mediated perturbations of -synuclein localization could cause pathology in both LRRK2-PD, and idiopathic PD.

neuroscience↗